OncoMatch/Clinical Trials/NCT07230405
A Phase II Study of SKB571 in Patients With Lung Cancer
Is NCT07230405 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SKB571 for for lung cancer (non-small cell).
Treatment: SKB571 for — This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
locally advanced or metastatic NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Subjects who have received chemotherapy...within 4 weeks prior to the first dose of study treatment
Cannot have received: immunotherapy
Subjects who have received...immunotherapy...within 4 weeks prior to the first dose of study treatment
Cannot have received: biological therapy
Subjects who have received...biological therapy within 4 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify